- Conditions
- Cancer
- Interventions
- BMS-906024
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Atlanta, Georgia • Detroit, Michigan + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2401–2424
of 4,780
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma
- Interventions
- dexamethasone, clarithromycin, Pomalidomide
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Kidney Cancer, Renal Cell Carcinoma
- Interventions
- HSPPC-96
- Biological
- Lead sponsor
- Agenus Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 5
- States / cities
- San Francisco, California • Stanford, California • Hackensack, New Jersey + 2 more
- Conditions
- Multiple Myeloma, Plasma Cell Leukemia
- Interventions
- Fludarabine/Busulfan x 4 days, stem cell transplant
- Drug · Procedure
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Uterine Fibroids
- Interventions
- Telapristone Acetate, Placebo
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 47 Years · Female only
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
- Conditions
- Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible, Newly Diagnosed Multiple Myeloma (NDMM)
- Interventions
- Elranatamab (PF-06863135), Daratumumab and Hyaluronidase-fihj, Lenalidomide, Bortezomib for Injection, Dexamethasone
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Multiple Myeloma
- Interventions
- Comprehensive Geriatric Assessment, Qualitative patient-care partner interviews, Surveys on well-being and function
- Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Solid Tumor
- Interventions
- PF-07284892, lorlatinib, binimetinib, cetuximab, encorafenib
- Drug · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Detroit, Michigan + 6 more
- Conditions
- Plasma Cell Myeloma, Transplant-Related Carcinoma
- Interventions
- Ixazomib Citrate, Laboratory Biomarker Analysis, Lenalidomide
- Drug · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Dose Escalation, Safety, Preliminary Efficacy, Advanced Solid Tumors, Metastatic Breast Cancer, Advanced Pancreatic Adenocarcinoma, Metastatic Colorectal Cancer, Recurrent Glioblastoma Multiforme, Gastric Cancer, Gastroesophageal Junction Cancer, Triple Negative Metastatic Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
- Interventions
- LDE225, BKM120
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Francisco, California • Tampa, Florida + 9 more
- Conditions
- Pancreatic Cancer
- Interventions
- SM-88 used with MPS (methoxsalen, phenytoin, sirolimus), Capecitabine, Gemcitabine, and 5-FU
- Drug
- Lead sponsor
- Tyme, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Duarte, California • Santa Monica, California + 13 more
- Conditions
- Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia, Accelerated Phase, Chronic Myelogenous Leukemia, Blastic Phase, Myelodysplastic Syndromes, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non Hodgkin Lymphoma, Graft Vs Host Disease, Graft-versus-host-disease
- Interventions
- Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine), Methotrexate, Mycophenolate Mofetil (MMF), Cyclophosphamide
- Drug · Procedure
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 3 Years to 39 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 4 more
- Conditions
- Multiple Myeloma
- Interventions
- BCMA CART + huCART19, CART BCMA or CART BCMA + huCART19, Single-dose infusion of CART BCMA or CART BCMA + huCART19
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2036
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer), Advanced Solid Tumors
- Interventions
- ALTA3263, cetuximab, mFOLFOX6, Pembrolizumab, Pemetrexed + Cisplatin /Carboplatin, mFOLFIRINOX, GnP, Midazolam
- Drug
- Lead sponsor
- Alterome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 14
- States / cities
- Orlando, Florida • Tampa, Florida • Boston, Massachusetts + 7 more
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- ascorbic acid, arsenic trioxide, bortezomib, dexamethasone, thalidomide, Aspirin
- Dietary Supplement · Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Breast Cancer, Colon Cancer
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 2,517 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 15
- States / cities
- Orange, California • Colorado Springs, Colorado • Hartford, Connecticut + 12 more
- Conditions
- Multiple Myeloma
- Interventions
- Melphalan, Bortezomib
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Hackensack, New Jersey
- Conditions
- Hypoactive Sexual Desire Disorder
- Interventions
- testosterone gel, placebo gel
- Drug
- Lead sponsor
- BioSante Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 3,656 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 141
- States / cities
- Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 116 more
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2032
- U.S. locations
- 2
- States / cities
- Charlotte, North Carolina • Winston-Salem, North Carolina
- Conditions
- Relapsed Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Ixazomib, Lenalidomide, Dexamethasone, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 722 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 18
- States / cities
- Little Rock, Arkansas • Anaheim, California • Berkeley, California + 15 more
- Conditions
- Metastasis From Malignant Tumor of Prostate (Disorder)
- Interventions
- 64Cu-PSMA I&T
- Drug
- Lead sponsor
- Curium US LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 9
- States / cities
- New Haven, Connecticut • Hines, Illinois • Baltimore, Maryland + 3 more
- Conditions
- Smoldering Multiple Myeloma
- Interventions
- Selinexor
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Malignant Epithelial Mesothelioma, Adenocarcinoma of the Pancreas, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma of the Ovaries
- Interventions
- CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin
- Biological
- Lead sponsor
- Anza Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Bethesda, Maryland • Philadelphia, Pennsylvania
- Conditions
- Multiple Myeloma
- Interventions
- Granix, High dose melphalan (HDR), Autologous Stem Cell Transplant (ASCT)
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- St Louis, Missouri